125 related articles for article (PubMed ID: 15788685)
1. Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model.
Zhang X; Galardi E; Duquette M; Delic M; Lawler J; Parangi S
Clin Cancer Res; 2005 Mar; 11(6):2337-44. PubMed ID: 15788685
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
Zhang X; Galardi E; Duquette M; Lawler J; Parangi S
Clin Cancer Res; 2005 Aug; 11(15):5622-30. PubMed ID: 16061881
[TBL] [Abstract][Full Text] [Related]
3. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model.
Zhang X; Connolly C; Duquette M; Lawler J; Parangi S
Cancer Lett; 2007 Mar; 247(1):143-9. PubMed ID: 16757110
[TBL] [Abstract][Full Text] [Related]
4. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin.
Zhang X; Xu J; Lawler J; Terwilliger E; Parangi S
Clin Cancer Res; 2007 Jul; 13(13):3968-76. PubMed ID: 17606731
[TBL] [Abstract][Full Text] [Related]
5. Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
Matuszewska K; Ten Kortenaar S; Pereira M; Santry LA; Petrik D; Lo KM; Bridle BW; Wootton SK; Lawler J; Petrik J
Gynecol Oncol; 2022 Jan; 164(1):154-169. PubMed ID: 34799137
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.
Russell S; Duquette M; Liu J; Drapkin R; Lawler J; Petrik J
FASEB J; 2015 Feb; 29(2):576-88. PubMed ID: 25395453
[TBL] [Abstract][Full Text] [Related]
8. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
Scholz A; Wagner K; Welzel M; Remlinger F; Wiedenmann B; Siemeister G; Rosewicz S; Detjen KM
Gut; 2009 Feb; 58(2):261-70. PubMed ID: 18829975
[TBL] [Abstract][Full Text] [Related]
9. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
10. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer.
Stephan S; Datta K; Wang E; Li J; Brekken RA; Parangi S; Thorpe PE; Mukhopadhyay D
Clin Cancer Res; 2004 Oct; 10(20):6993-7000. PubMed ID: 15501979
[TBL] [Abstract][Full Text] [Related]
11. A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR.
Ren B; Song K; Parangi S; Jin T; Ye M; Humphreys R; Duquette M; Zhang X; Benhaga N; Lawler J; Khosravi-Far R
Cancer Res; 2009 May; 69(9):3856-65. PubMed ID: 19366809
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
13. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
Bockhorn M; Tsuzuki Y; Xu L; Frilling A; Broelsch CE; Fukumura D
Clin Cancer Res; 2003 Sep; 9(11):4221-6. PubMed ID: 14519649
[TBL] [Abstract][Full Text] [Related]
14. Treatment of human pancreatic cancer in mice with angiogenic inhibitors.
Prox D; Becker C; Pirie-Shepherd SR; Celik I; Folkman J; Kisker O
World J Surg; 2003 Apr; 27(4):405-11. PubMed ID: 12658482
[TBL] [Abstract][Full Text] [Related]
15. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
[TBL] [Abstract][Full Text] [Related]
16. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant human canstatin protein in the treatment of pancreatic cancer.
He XP; Li ZS; Zhu RM; Tu ZX; Gao J; Pan X; Gong YF; Jin J; Man XH; Wu HY; Xu AF
World J Gastroenterol; 2006 Nov; 12(41):6652-7. PubMed ID: 17075979
[TBL] [Abstract][Full Text] [Related]
18. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
20. The novel hypoxic cell radiosensitizer, TX-1877 has antitumor activity through suppression of angiogenesis and inhibits liver metastasis on xenograft model of pancreatic cancer.
Miyake K; Shimada M; Nishioka M; Sugimoto K; Batmunkh E; Uto Y; Nagasawa H; Hori H
Cancer Lett; 2008 Dec; 272(2):325-35. PubMed ID: 18762366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
